Press "Enter" to skip to content

Bluebird bio, Bristol-Myers’ multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Original source:

Also Read:   Zydus Cadila gets tentative nod from USFDA to market Parkinson's disease drug